Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Ocular Therapeutix Inc OCUL

Healthcare Biotechnology
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as... see more

Current News (NDAQ:OCUL)

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 22 hours ago

Ocular Therapeutix(TM) Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

GlobeNewswire 2 days ago

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 23, 2026

Ocular Therapeutix(TM) Appoints David W. Robinson as Global Chief Commercial Officer

GlobeNewswire January 21, 2026

Ocular Therapeutix(TM) Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI(TM) in Wet AMD

GlobeNewswire December 8, 2025

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 5, 2025

Ocular Therapeutix(TM) Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI(TM) in NPDR

GlobeNewswire November 24, 2025

Ocular Therapeutix(TM) to Participate in November and December Investor Conferences

GlobeNewswire November 12, 2025

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 7, 2025
View More News ››

Opinion & Analysis (NDAQ:OCUL)

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data

Streetwise Reports March 5, 2020
View More Opinion ››

Bullboard Posts (NDAQ:OCUL)

Using technical analysis for this stock.

This stock is signalling strength to the upside for shareholders today anyway
coolfooldumbguy - January 15, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL): Innovative Therapies

http://beyondspx.com/2024/07/31/ocular-therapeutix-inc-nasdaqocul-innovative-therapies-driving-growth-in-retinal-diseases/
MikeTester - August 2, 2024

4 SMALL-CAP BIOTECH STOCKS FOR YOUR INVESTMENT PORTFOLIO!

$OCUL $LPTX $VYGR $MNMD   Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of...
AviseAnalytics - November 1, 2021

OCUL Predictions

The current release of OCUL's therapeutics and new expectations for products, as well as the average stock price, led to the upward...
BluSignals - October 3, 2018
View more Bullboard ››

Green Bridge Metals Corporation

Green Bridge Metals Corporation

Green Bridge Metals Corporation engages in the acquisition, exploration, and development of mining projects in Canada. The ...
View More »

Podcasts